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ABSTRACT 
Multiwalled carbon nanotube (MWCNT) length is suggested to critically determine their 
pulmonary toxicity. This stems from in vitro and in vivo rodent studies and in vitro human 
studies using cell lines (typically cancerous). There is little data using primary human lung cells. 
We addressed this knowledge gap, using highly relevant, primary human alveolar cell models 
exposed to precisely synthesized and thoroughly characterized MWCNTs. In this work, 
transformed human alveolar type-I-like epithelial cells (TT1), primary human alveolar type-II 
epithelial cells (ATII) and alveolar macrophages (AM) were treated with increasing 
concentrations of MWCNTs before measuring cytotoxicity, inflammatory mediator release and 
MAP kinase signalling. Strikingly, we observed that short MWCNTs (~0.6 μm in length) induced 
significantly greater responses from the epithelial cells, whilst AM were particularly susceptible 
to long MWCNTs (~20 μm). These differences in the pattern of mediator release were associated 
with alternative profiles of JNK, p38 and ERK1/2 MAP kinase signal transduction within each 
cell type. This study, using highly relevant target human alveolar cells and well defined and 
characterized MWCNTs, shows marked cellular responses to the MWCNTs that vary according 
to the target cell type, as well as the aspect ratio of the MWCNT.  
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1. Introduction 
Carbon nanotubes (CNT) are receiving ever-increasing attention due to their unique 
structural characteristics offering high strength to weight ratios, improved conductivity and 
thermal stability e.g. CNT fillers in polymers result in CNT/polymer composites with 
significantly improved thermal or electrical conductivity compared to the polymer alone [1,2]. 
Typically occurring with diameters in the 10 - 100 nm range and with lengths often extending 
much greater than 1 μm, CNTs are being applied in areas such as electronics, automotive, 
aerospace and medical industries [3]. The application of these materials to consumer products is 
certain to expand significantly and the risk of exposure to humans is therefore also set to 
significantly increase.  Human exposure to CNTs may occur at the initial synthesis stage of the 
material, during the industrial application and incorporation of the material into products and 
subsequently throughout the life cycle of the CNT composite material/products. The biological 
reactivity of CNTs is likely to depend on their physicochemical properties, including their 
structure (single-walled or multi-walled; SWCNT or MWCNT respectively), their length, 
diameter, surface charge, aggregative state and synthesis catalyst impurities.  
 
The inhalation of some engineered nanomaterials, such as MWCNTs, is potentially a significant 
human health concern. Evidence for this from existing studies shows the adverse effects of 
inhaled air pollution particles (which contains an ultrafine component that is analogous in size to 
engineered nanomaterials) on the cardiopulmonary system [4]. A large portion of inhaled nano-
sized particles deposit in the alveolar unit [5] where the active gas-blood interface has a tight-
junctional cellular barrier composed of type-I (ATI) and type-II (ATII) epithelial cells abutting 
the capillary endothelial cells for effective gas exchange. Although there are approximately equal 
numbers of ATI and ATII cells within the alveolar unit, the thin, attenuated ATI epithelial cells 
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cover 95% of the alveolar surface [6]. Cuboidal ATII cells synthesise, secrete and recycle 
surfactant, modulate both fluid balance and host defense and can terminally differentiate into 
ATI cells, where gas exchange occurs by diffusion. Resident alveolar macrophages (AM) police 
the airspaces, removing inhaled particles, pathogens and cellular debris.  
 
In early MWCNT studies by Shvedova et al (mouse pharyngeal aspiration exposure to 
SWCNTs) and Muller et al (rat intratracheal instillation exposure to MWCNTs), MWCNTs were 
found to persist in the lung for up to 60 days post exposure, elicit dose-dependent increases in 
lung cell inflammation, stimulate oxidative stress markers in lung tissue and induce early onset 
of lung fibrosis [7,8]. Significantly, the biopersistent, fibrous nature of MWCNTs renders them 
somewhat comparable to the well-studied lung toxicant, asbestos. Evidence suggests that long, 
thin, needle-like and biopersistent fibers (e.g. amphibole asbestos) are involved in the 
development of pulmonary mesothelioma (an incurable cancer largely due to asbestos exposure), 
while both long and short asbestos fibers contribute to fibrosis and the development of asbestosis 
(a chronic inflammatory and fibrotic pathology) [9].  
 
MWCNT length may play a significant role in the nature of any MWCNT-induced lung cell 
bioreactivity. Indeed, recent studies by Mühlfeld et al and Murphy et al have shown that the 
MWCNT length can determine the inflammatory responses and morphological characteristics of 
mouse lung parenchyma post treatment, while MWCNT length is also critical in THP-1-derived 
macrophage activation and subsequent pro-inflammatory responses from adjacent Met5A 
mesothelial cells [10-12]. While these studies highlight MWCNT length as a potential 
determinant of pulmonary toxicity, significant challenges in precisely synthesising MWCNTs, so 
that just one physicochemical property is changed while all others remain identical, make it 
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difficult to determine the role of a single, specific physicochemical property in bioreactivity of 
MWCNTs. 
 
Furthermore, while the ever-expanding research effort into MWCNT pulmonary toxicity is 
beginning to reveal some important mechanisms by which these materials may induce cellular 
bioreactivity in the lung (recently reviewed by Donaldson et al [13]), there is a paucity of 
experimental data using primary human lung cells. This is a critical knowledge gap, as it is well 
known, for example, that cellular processes and mediators differ between species and thus the 
relevance of some in vitro screening studies, which utilize non-human material and cell lines, is 
unclear. There is therefore a crucial need for more studies of relevant human pulmonary cell 
models. Additionally, human ATI epithelial cells remain very poorly studied, despite their 
significant relevance in nanomaterial deposition in the respiratory units after inhalation of 
nanosized materials. Therefore, in this study, we chose to study the bioreactivity of MWCNT 
length using highly relevant primary human ATII and AMs (from the same subjects) and human 
alveolar type-I-like epithelial cell line (TT1) generated in-house [14]. We hypothesized that three 
thoroughly-characterised MWCNTs formats (each with a different length but, importantly, 
maintaining a comparable diameter, surface charge and carbon purity i.e. % atomic carbon) 
would exhibit adverse effects on primary human alveolar epithelium and alveolar macrophages, 
such that the long MWCNTs, with similar lengths to those of amphibole asbestos implicated in 
the development of mesothelioma, would exert the most deleterious response, whilst shorter 
MWCNTs would be less bioreactive.  
2. Experimental 
 
2.1 Physicochemical characterisation of carbon nanotubes 
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Non-functionalised, MWCNTs (synthesised by chemical vapor deposition), denoted 
MWCNT-0.6μm, MWCNT-3μm and MWCNT-20μm, were purchased from Nanothinx, Greece. 
MWCNT surface charge (as zeta potential) was determined by zeta-meter using a Zetasizer Nano 
by Malvern Instruments (Worcestershire, UK). All MWCNT samples were suspended in 
deionised water and DCCM-1 culture medium to determine any alteration of physiochemical 
characteristics. The respective length and diameter distribution of each MWCNT sample was 
determined by transmission electron microscopy using a Hitachi 7100 TEM, while the respective 
agglomerative state of each MWCNT format was determined by scanning electron microscopy 
using a Carl Zeiss Ultra Plus Field emission SEM. The suspension stability was estimated by 
zeta potential measurements, using Malvern ZetaSizer Nano. Elemental mapping, to determine 
the nature and degree of MWCNT impurities, was also performed using a Carl Zeiss Ultra Plus 
Field emission SEM in energy-dispersive mode for X-ray spectroscopy (EDX). All three 
MWCNT samples were assayed for endotoxin contamination, using a Pierce LAL Chromogenic 
Endotoxin Quantitation Kit (Thermo Scientific, UK) and all three were below the 0.1 EU/mL 
limit of detection. BET surface area measurements were performed on Beckman Coulter SA3100 
(Beckman Coulter Inc., USA).  
 
 
 
 
2.2 Ethics Statement  
The human lung tissue used in this study was surplus tissue obtained following resection 
for lung carcinoma. Written informed consent was obtained for all samples and the study was 
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carried out with the approval of the Royal Brompton and Harefield Ethical Committee (Ref: 
08/H0708/73). 
 
2.3 Cell models 
Primary human ATII cells and AMs were isolated from human lung of grossly normal 
appearance obtained following resection for lung carcinoma, as described by Thorley et al [15].  
Cells were isolated from a minimum of three subjects per experiment, with a total of fifteen 
subjects used in this study.  Briefly, lung tissue sections were perfused by injection of 0.15 M 
sterile sodium chloride saline solution until the draining lavage ran clear and the cell count was < 
1x104 cells/ml. The saline perfusate was collected and centrifuged at 1300rpm for 10 minutes at 
20oC. The cell pellet was re-suspended in serum-free RPMI cell culture medium containing 1% 
penicillin/streptomycin/L-glutamine (PSG) and plated on 96 well culture plates at 0.2 x106 
AMs/well. After AM adherence (approximately three hours), culture medium was removed and 
non-adherent cells were removed by phosphate buffered saline (PBS) washing. AM cultures 
were then maintained in serum-free RPMI cell culture medium containing 1% PSG. 
 
The tissue was then prepared for ATII cell isolation by perfusing with trypsin (0.25% in Hanks 
balanced salt solution) and incubating at 37oC for 45 minutes; trypsin was replaced twice during 
the incubation period. The tissue was then finely chopped in the presence of newborn calf serum 
(NCS), shaken for five minutes with DNase (250 μg/ml) at room temperature and passed through 
a 400μm filter followed by a 40 μm filter to remove large tissue debris. The cell-containing filtrate 
was then centrifuged at 1300 rpm for 10 minutes and the resulting pellet was re-suspended in 
DCCM-1 culture medium containing 50 μg/ml DNase. Cells were then incubated in tissue culture 
flasks for two hours (humidified incubator, 5% CO2/95% air at 37°C) to allow differential 
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adherence and removal of contaminating mononuclear cells. Non-adherent ATII cells were 
removed after 2 hours and the cell suspension was centrifuged at 1300 rpm for 10 minutes. The 
resulting pellet was re-suspended in a DCCM-1 culture medium containing 10%NCS and 1% 
PSG and cells were seeded on 96 well culture plates at 0.1 x106 cells/well. The 96 well culture 
plates were previously coated with 50 μl of 1% PureCol collagen solution (Leimuiden, 
Netherlands; Type I collagen) and allowed to air dry. Cells reached confluence after 48 hours. 
These cells have been thoroughly characterised using electron microscopy, which shows that the 
cells are cuboidal in morphology, have surfactant-containing lamellar bodies, tight junctions and 
microvilli. Furthermore they stain positively for the ATII cell marker alkaline phosphatase and 
express surfactant proteins A and C and maintain their phenotype for up to six days [16,17].  
 
This laboratory has previously immortalised human ATI-like cells (derived from freshly isolated 
and cultured primary human ATII cells) using transduction with the catalytic subunit of 
telomerase (human telomerase reverse transcriptase; hTERT) and a temperature sensitive mutant 
of simian virus 40 large-tumour antigen [14]. These ATI-like (transformed type-I-like; TT1) 
cells, the first human ATI-like cell line to be produced, are negative for the ATII cell markers 
SP-C, alkaline phosphatase and thyroid transcription factor-1. Moreover, TT1s do not contain 
lamellar bodies. They display a thin, attenuated morphology containing vesicles, being caveolae 
positive. TT1 cells were cultured to confluence in 96-well culture plates using DCCM-1 tissue 
culture medium with 10 % FCS new-born calf serum, 0.05% G418 and 10% PSG. An initial cell 
seeding of 0.1 x 106/well yielded a confluent monolayer after 48 hours. Growth medium was 
replaced with serum-free DCCM-1 24 hours prior to MWCNT exposure. Cells were incubated in 
humidified 5% CO2/95% air at 37°C. 
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TT1 and ATII cells possess the ability to spread and divide, unlike AMs. Consequently, the final 
cell numbers in confluent TT1 and ATII monolayers could not be determined from the initial 
number of seeded cells. Similarly, some of the plated AMs may not adhere. Such a potential 
discrepancy in seeded and actual final cell numbers, when significant, would influence the 
determination cytokine and chemokine activity when comparing responses between cell types. 
Confluent monolayers of each cell type were therefore imaged under light microscope (100X 
magnification) and counted manually. We determined that final TT1, ATII and AM cell numbers 
per well were comparable (data not shown). 
 
 
2.4 Treatment of TT1 cells, ATII cells and AMs with MWCNTs  
Respective MWCNT format doses were prepared in fresh serum-free DCCM-1 or RPMI 
culture medium for subsequent TT1 cell, ATII and AM exposure. It was favorable to freshly 
prepare the MWCNT doses immediately prior to cell exposure. Each MWCNT dose preparation 
was sonicated in a sonicating water bath (135W, 42 kHz; VWR) for 30 seconds prior to cell 
culture exposure.  
 
 
2.5 Choice of dose metric 
The choice of dose metric in nanomaterial toxicology studies (e.g. particle mass, particle 
number, particle surface area) is a contentious issue [18-21]. While we appreciate that there are 
relative merits to each of these, we have chosen to present our data with a mass dose metric, 
using a wide concentration range; this facilitates a useful comparison of our study with similar in 
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vitro studies evaluating MWCNT length in cellular reactivity and where mass is used as a dose 
metric (e.g. [12,22,23]). 
 
 
2.6 Measurement of cell viability  
The effect of each of the three MWCNT formats on AM, TT1 and ATII cell viability, at 
24 hours, was assessed using an MTT and an LDH assay of respective cell cultures. Briefly, post 
MWCNT exposure, culture medium was removed to a new 96 well plate for lactate 
dehydrogenase (LDH) analysis. This plate was centrifuged at 3000 rpm for 20 minutes at 4oC to 
remove any MWCNTs that might have interfered with subsequent optical absorbance readings. 
The supernatant was assayed using the LDH assay (Roche Diagnostics, Germany) according to 
the manufacturer's protocol. For the MTT assay, treated cells were washed three times with PBS 
to remove residual MWCNT particles. Cells were then incubated with 3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) prepared at 50 μg/ml in fresh serum-free DCCM-1 or 
RPMI culture medium, for 2 hours at 37oC. The culture medium/MTT solution was then 
removed and replaced with 200 μl DMSO. After gently pipetting this solution up and down to aid 
solubilisation of mitochondria associated formazan, the contents of each well were transferred to 
a corresponding 96 well (V bottomed) centrifuging plate. This plate was then centrifuged at 3000 
rpm for 20 minutes at 4oC to remove any MWCNTs that might have interfered with subsequent 
optical absorbance readings. Supernatant absorbance at 570nm was measured in a 
SPECTRAFluor Plus microplate spectrophotometer (TECAN, Italy). Cell viability of treated 
cells was calculated as a percentage of the vehicle control (cell culture medium). Exposures for 
MTT and LDH assays were repeated in triplicate using three separate TT1 cell passages and 
matched ATII cells and AMs from four subjects. We have established that the MWCNTs used in 
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this study do not interfere with the solubilisation of formazan and therefore do not interfere with 
the MTT cell viability assay (data not shown). 
 
2.7 Measurement of cytokines and chemokines by ELISA 
Exposures were repeated in triplicate using three separate TT1 cell passages and ATII 
cells and AMs from four subjects. Mediator-conditioned medium from MWCNT-exposed TT1 
cell, ATII cell and AM cultures was assayed for concentrations of inflammatory cytokines 
(human IL-6) and inflammatory chemokines (human IL-8 and MCP-1) using sandwich enzyme-
linked immunosorbent assays (ELISA). The assays were performed using DuoSet® antibody kits. 
The manufacturer’s directions (R&D systems, USA) were followed. 
 
2.8 Inhibition of the MAP kinases JNK, p38 and ERK 1/2 in TT1 cells, ATII cells and AMs 
To assess the involvement of individual MAP kinases in MWCNT-mediated 
inflammatory mediator secretion, cultures of TT1 cells, ATII cells and AMs were incubated for 
30 minutes with 10 μM of commercially available inhibitors to: p38 (SB203580), ERK 1/2 
(PD98059) (New England Biolabs, Hitchin UK) and JNK (SP600125) (Sigma-Aldrich, Poole 
UK), prior to exposure to the 50 μg/ml of MWCNT-0.6μm, MWCNT-3μm or MWCNT-20μm 
formats for 24 hours. Exposures were repeated in triplicate using three separate TT1 cell 
passages and ATII cells and AMs from four subjects. Mediator-conditioned medium, from each 
of the MAP-kinase-inhibition exposure conditions, was assayed for concentrations of the 
inflammatory mediators human IL-6, IL-8 and MCP-1 using ELISA as previously described. 
Western blot analysis confirmed successful inhibition of respective MAP kinases in all three cell 
types (data not shown). 
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2.9 Statistical Analysis 
Data from MTT, LDH, ELISA, and MAP kinase experiments is presented as the mean ± 
standard error (where three independent experiments were performed using three separate TT1 
passage generations and where four independent experiments were performed using four 
separate donor tissues for ATII and AM studies). Significant differences in MWCNT 
(format/dose) treatment on cell viability, cytokine/chemokine release and significant effects of 
MAP kinase inhibition on cellular responses were determined using a parametric one-way 
analysis of variance with Bonferroni comparisons (for TT1 cell line experiments) and using a 
non-parametric Kruskal–Wallis test followed by a Mann–Whitney test where appropriate (for 
ATII and AM primary cell experiments). In all analyses, a P value <0.05 was considered 
significant. 
 
 
 
 
 
 
3. Results and Discussion 
3.1 Physicochemical properties of selected carbon nanotubes 
Transmission electron microscopy (TEM) characterisation of the three non-functionalised 
MWCNT formats, MWCNT-0.6μm, MWCNT-3μm and MWCNT-20μm (as labeled by the 
manufacturer, Nanothinx Greece, and as denoted throughout the article), revealed MWCNTs 
with median lengths of 1.1 μm (0.23 – 9.7 μm), 4.3 μm (0.5 - 24.4 μm) and 19.3 μm (0.6 - 30.8 μm) 
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respectively (length ranges in parenthesis). Each MWCNT format had comparable median 
diameters (ranges in parenthesis): 30.6 nm (19.5 - 47.6 nm), 33.3 nm (22.6 - 45.8 nm) and 27.8 
nm (15.6 - 41.9 nm) for MWCNT-0.6μm, MWCNT-3μm and MWCNT-20μm respectively 
(Figures 1 and 2). Brunauer, Emmett and Teller (BET) measurements indicated that MWCNT-
0.6μm, MWCNT-3μm and MWCNT-20μm had surface areas of 255.24, 213.64 and 204.8 m2/g 
respectively. Personal communication with the manufacturer revealed that the 95% purity of 
MWCNT-20μm is achieved “as synthesised” with no post-synthesis chemical purification 
treatment. The manufacturer also detailed that MWCNT-20μm was shortened using a proprietary 
sonication method to produce MWCNT-0.6μm and MWCNT-3μm (although the manufacturer did 
not disclose the sonication medium, the comparable surface area and relatively low oxygen 
variation among samples suggests minimal surface modification).  
 
Each MWCNT format had reasonably comparable carbon purities (i.e the % atomic carbon) of 
87, 93 and 95% for MWCNT-0.6μm, MWCNT-3μm and MWCNT-20μm respectively as 
determined by EDX spectroscopy (Figure 3). While we did observe a difference in oxygen 
content between the MWCNTs, the atomic % variation on oxygen content was below 10% for all 
MWCNTs, as determined by EDX spectroscopy. The metal synthesis catalysts for these 
MWCNTs was not disclosed by the manufacturer, however we believe these are likely to be 
aluminum (accounting for 0.6, 0.5 and 0.3% of total atomic content for MWCNT-0.6μm, 
MWCNT-3μm and MWCNT-20μm respectively) and iron (<0.1% for any of the MWCNT 
formats), as determined by EDX spectroscopy. The surface charge of all three MWCNTs was 
also comparable at -13.2, -15.7 and -12 mV for MWCNT-0.6μm, MWCNT-3μm and MWCNT-
20μm respectively. A summary of the physicochemical characterisation in non-biological 
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medium (deionised water) and DCCM-1 cell culture medium, for all three MWCNT formats, is 
shown in Table 1. 
 
Table 1. Characterisation of MWCNTs.  
 
 
 
1μm 
(A) (B) (C) 
 
Figure 1. TEM micrographs of (A) MWCNT-0.6μm, (B) MWCNT-3μm and (C) MWCNT-20μm. 
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Figure 2. Length and diameter distribution of MWCNTs used in the present study. Length 
distributions were characterised for each MWCNT format, based on a total of 100 counts per 
format (A). Diameter distributions were characterised for each MWCNT format, based on a total 
of 100 counts per format (B). 
 
 
 
 
 
 
 
 
  
 
16
 
 
 
 
 
Figure 3. Measurement of MWCNT purity. The elemental composition of each MWCNT format 
was analysed by EDX spectroscopy, the observations of which are presented here using atomic 
% representation. 
 
 
 
 
 
 
 
 
 
3.2 Cell viability 
The effect of MWCNT length on TT1, ATII and AM cell viability (from 0.1 to 100  
μg/ml) was assessed over a 24-hour exposure period (Figure 4; viability was also assessed at 4 
hours, however no significant changes were observed; data not shown). Because certain 
MWCNTs have been shown to interfere in some cell viability assays [24], we performed two 
experimentally distinct assays (MTT and LDH assays) to validate our cell viability conclusions. 
In the MTT assay, TT1 cell viability remained unchanged up to 10 μg/ml, regardless of MWCNT 
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length (Figure 4A). Small but significant decreases in TT1 cell viability (up to 20%) did occur at 
higher MWCNT doses (50 and 100 μg/ml), however these doses are unlikely to be 
physiologically relevant to human health. As with TT1 cells, ATII cell viability remained 
unchanged for all MWCNT format exposures at low doses that are more likely to be 
physiologically relevant (up to 10 μg/ml; Figure 4A), only falling at the highest doses, by 15-
20%. Of all three lung cell types, AMs displayed the greatest reduction in cell viability following 
treatment with MWCNTs of all test lengths (Figure 4A). Even at the relatively low dose of 5 
μg/ml, MWCNT-20μm caused 20% AM cell death (P < 0.05). Striking decreases in AM viability 
were found following exposure to higher doses of MWCNT-20μm (up to 40%). This may be due 
to the primarily phagocytic nature of AMs, rendering them vulnerable to complicated 
interactions with MWCNTs with a high aspect ratio equal to, or greater than their own diameter. 
While beyond the aims of the present study, this phenomenon, termed ‘frustrated phagocytosis’, 
has been observed by Murphy et al following treatment of THP-1 macrophage cell line with high 
aspect ratio MWCNTs; MWCNTs of 13 – 36 μm in length and 85 – 165 nm in diameter 
stimulated the release of the acute phase inflammatory mediators IL-1β, TNFα, IL-6 and IL-8 
from treated THP-1 macrophages while shorter MWCNTs had no such effect [12]. Additionally, 
using mouse AMs, Hirano et al reported that MWCNTs associate with the plasma membrane of 
AM and induce cell death by rupturing the cell membrane [25] while Cheng et al have shown 
that MWCNTs pierce the membranes of human macrophages [26]; this may be one mechanism 
for the MWCNT-induced AM cell death seen in the present study. The reduction in AM viability 
in response to shorter MWCNT formats (MWCNT-0.6μm and MWCNT-3μm), while still 
significant at doses from 10 to 100 μg/ml, and relatively greater than that seen in epithelial cells, 
was significantly less than (~15%) responses seen following exposure to the longer MWCNTs.  
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Using the LDH release cytotoxicity assay, the trend in the degree of damage and reduction in cell 
viability reflected that observed in the MTT assay, where short MWCNTs caused more LDH 
release from epithelial cells and long MWCNTs caused most release from AMs (Figure 4B). 
However, the magnitude of cytotoxicity as measured by LDH release was less than that 
measured using the MTT assay. For example, an MTT-determined 38% reduction in AM cell 
viability following treatment with 50 μg/ml of MWCNT-20μm, measured as a 22% reduction 
when the LDH release assay was used for the same treatment. Nevertheless, the agreement 
between these two distinct assays, in terms of the trend in cell viability reduction, verifies our 
cell viability observations.   
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Figure 4. Viability of TT1 and ATII epithelial cells and AMs following 24 hours treatment with 
MWCNT-0.6μm, MWCNT-3μm and MWCNT-20μm, as determined by (A) MTT assay and (B) 
LDH assay. Data is presented as a % of the untreated control; significance is shown where *P < 
0.05, **P < 0.01 ***P < 0.001. 
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3.3 Inflammatory cytokine and chemokine release  
Based on cell viability data, a dose range of 0 – 50 μg/ml was chosen for inflammatory 
mediator release studies. Following 24-hour treatment (inflammatory mediators were also 
assessed at 4 hours treatment, however no significant changes were observed; data not shown) 
we found that differential responses to MWCNT lengths were critically dependent on the cell 
type being exposed. The TT1 and ATII epithelial cells were significantly more responsive to the 
shorter MWCNTs (MWCNT-0.6μm and MWCNT-3μm) than to the long MWCNT-20μm formats 
following 24 hour treatment (Figure 5). For example, 10 μg/ml of MWCNT-0.6μm induced a 
significant 4.7-fold increase in interleukin-8 (IL-8) release from ATII cells (P < 0.05) while the 
same dose of MWCNT-20μm induced only a 1.6-fold increase in IL-8 release. The profile of 
ATII IL-8 release, following treatment with MWCNT-3μm, was similar to that of MWCNT-
0.6μm. Even very low doses, 0.1 and 1.0 μg/ml, of MWCNT-0.6μm and MWCNT-3μm (0.1 and 1 
μg/ml) were sufficient to evoke significant increases in interleukin-6 (IL-6) and IL-8 release from 
treated ATII cells e.g. more than a two-fold increase in IL-8 release following MWCNT-0.6μm 
treatment at these low doses. TT1 and ATII monocyte chemoattractant protein-1 (MCP-1) 
release was also increased; again, the greatest increases were seen following treatment with the 
shortest MWCNTs (Figure 5); at very low doses, where there were striking increases in MCP-1 
release by both TT1 and ATII cells. IL-8 and MCP-1 are proinflammatory chemokines, 
functioning in neutrophil and monocyte attraction to sites of cellular inflammation. Notably, 
increased release of IL-6 (a pleiotropic cytokine important in inflammation) is associated with 
the pathogenesis of numerous lung diseases such as asthma [27], chronic obstructive pulmonary 
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disease [28] and idiopathic pulmonary fibrosis [29]. IL-6 has been shown to readily translocate 
from the lung to systemic circulation upon exposure to particulate matter [30] and it is also a 
robust predictor of cardiovascular disease in humans [31]. Therefore, the finding of a 
concentration-dependent increase in IL-6 release by TT1 and ATII cells is significant. Thus, in 
the present study we have shown that inhalation of very small amounts of short MWCNT and 
deposition in the respiratory units, would be would be very likely to induce inflammation within 
the human alveolar unit, even in the absence of cell death. 
 
In contrast to the findings with the alveolar epithelial cells, the longest (MWCNT-20μm) format 
was the most bioreactive with AMs, inducing the greatest IL-6 and IL-8 release following 24 
hour treatment (Figure 5). The differential response was most marked for IL-8 release, where 10 
μg/ml of MWCNT-20μm induced a striking 7.8-fold increase in IL-8 release from AMs (P < 0.05) 
while the same dose of MWCNT-0.6μm induced only a 2.2-fold increase (P < 0.05). Even at very 
low doses of MWCNT-20μm (0.1 and 1.0 μg/ml), AM release of IL-6 and IL-8 was significantly 
increased. Thus, for very long MWCNTs that reach the human peripheral lung, our data indicates 
that even very low amounts would be capable of inducing substantial proinflammatory mediator 
release from resident AMs.  
 
There was a similar, but less marked, profile of response for AM IL-6 release, and both the 
shorter MWCNT formats induced IL-6 and IL-8, though not to the same extent as the long 
MWCNTs. However, in contrast to the IL-6 and IL-8 release profiles, there was almost no effect 
on MCP-1 release (Figure 5). Interestingly, this is very different from the TT1 and ATII 
epithelial cells, where even the long MWCNT-20μm format induced increases in MCP-1 release. 
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IL-6 and IL-8 have important roles in injured tissue with respect to the balance between 
inflammation and repair. The observed increase in AM release of IL-6 and IL-8 may be a result 
of extracellular receptor interactions or alternatively it may be in response to attempted 
internalisation of the long MWCNTs or incomplete phagocytosis. These AM observations 
complement the work of Murphy et al [12] who have described a similar response from a 
MWCNT-exposed THP-1 macrophage cell line. Indeed Palomaki et al have recently shown that 
long, needle-like MWCNTs activate the inflammasome complex in the cytoplasm of human 
monocyte-derived macrophages via engagement of toll-like receptors (TLR) [23]. Previous 
studies by us have shown that primary human AMs (and indeed primary human ATII cells and 
TT1 cells) abundantly express TLRs including TLR-2 and TLR-4 [32,33]. Considering this, and 
the well-established downstream TLR signaling connection with MAP kinases [34] (which were 
activated in the present study; discussed below), these extracellular receptors are potentially 
important for both short and long MWCNT interactions with alveolar epithelial cells and AMs. 
 
The phenomenon of differential MWCNT activity, based on length, has also been described by 
Liu et al [35]. In their study, they showed that treatment of RAW264.7 murine macrophages with 
long MWCNT (12.5 – 200 μg/ml; 3 - 14 μm in length, 40 – 60 nm in diameter (nominal values, 
material characterisation was not performed)) reduced cell viability to a greater extent than short 
MWCNTs (12.5 – 200 μg/ml; 1.5 μm in length, 40 – 60 nm in diameter (nominal values, material 
characterisation was not performed by the authors). However the same study reported that the 
shorter MWCNTs induced greater inflammatory mediator release (TNFα and IL-12) when 
compared to the longer MWCNTs; the greater number of viable cells may account for this 
however. Bussy et al recently reported on the effects of surface oxidation of MWCNTs (resulting 
from length shortening) on cellular reactivity in murine macrophages [22]. Here, the authors 
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found that shortened MWCNTs (~5μm in length; produced by sonicating MWCNTs of ~10μm in 
length) had increased surface oxygen and were more bioreactive than their parent MWCNTs.  
We also acknowledge that increased oxygen content may play some part in MWCNT 
bioreactivity. However, in the present study, while we did observe a small difference in oxygen 
content between the parent and shortened MWCNTs, the atomic percent variation on oxygen 
content was below 10% for all MWCNTs and unlikely to contribute, particularly since the short 
(9% oxygen) were most bioreactive with epithelial cells, whilst long (~4% oxygen) were most 
bioreactive with AMs, indicating that oxygen is unlikely to be a driving factor (Figure 3). 
Considering this, it is much more likely that MWCNT length is the critical determinant in human 
lung cell bioreactivity. The observations in the present study are also important as they highlight 
that the use of single cell type in vitro models, often employed in other studies and in industrial 
safety assessments, may not be sufficient to understand the risk of MWCNTs on human 
pulmonary health. For example, the alveolar epithelial cell study alone would deceptively 
indicate that long MWCNTs are not as important in bioreactivity within the human alveolar unit. 
Yet, our finding that treating human AMs with short MWCNTs had a lesser effect on mediator 
release when compared with long MWCNTs, suggests that particle length is an important 
regulatory factor in human AM activation. Similarly, the AM study alone would mislead us into 
thinking that induced MCP-1 release, and consequential monocyte recruitment, is not important; 
however this conclusion would neglect the substantial amount of MCP-1 produced by the 
intimately neighbouring alveolar epithelial cells following MWCNT treatment.  
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Figure 5. Inflammatory mediator release from TT1 and ATII epithelial cells and AMs following 
treatment with MWCNTs for 24 hours. Release of IL-6, IL-8 and MCP-1 from MWCNT-
exposed (1-50 μg/ml) TT1, ATII cells and AMs. Mediator release is presented as pg/ml; 
significant differences are indicated where * P < 0.05, ** P < 0.01 and *** P < 0.001. 
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3.4 Role of MAP kinase signalling in MWCNT bioreactivity with TT1 and ATII cells and 
AMs 
To further investigate the cellular processes leading to pro-inflammatory mediator release 
from TT1 and ATII epithelial cells and AMs upon exposure to MWCNTs of different lengths, 
we studied the potential involvement of MAP kinase signalling. Specific inhibition of JNK, p38 
and ERK 1/2, prior to MWCNT treatment, was achieved using 10 μM of each respective inhibitor 
(as previously optimised by Thorley et al [33]). Their effect on pro-inflammatory mediator 
release was then measured following treatment with each of the MWCNT formats (a 50μg/ml 
dose was chosen as it typically induced the greatest magnitude of mediator release, thus it would 
give us the best chance of seeing any effects of the MAP kinase inhibitors on reducing mediator 
release). 
  
SP600125 is a cell-permeable, selective inhibitor of JNK phosphorylation [36], SB203580 
inhibits p38 catalytic activity but does not inhibit the phosphorylation of p38 by upstream 
kinases [37] and PD98059 binds to the inactive forms of ERK 1/2, preventing activation by 
upstream activators [38]. In TT1 and ATII epithelial cells, inhibition of MAP kinases 
significantly reduced the magnitude of the cytokine and chemokine response to MWCNTs 
(Figure 6), with the exception of TT1 cell IL-6 release, which was minimally affected and 
significant only for MWCNT-0.6μm, where all three inhibitors caused a similar reduction 
(~15%). 
 
The greatest magnitude of change following TT1 treatment with MAP kinase inhibitors was 
observed for MWCNT-induced MCP-1 release. Inhibition of JNK, p38 and ERK 1/2 reduced the 
TT1 MCP-1 response to 50 μg/ml of short MWCNT-0.6μm by 48%, 40% and 38% respectively. 
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A generally similar inhibitory effect of MAP kinase inhibitors on MCP-1 release was found 
following MWCNT-3μm exposure, whilst the effect on MWCNT-20μm MWCNT exposure 
responses was less marked, but still highly significant. IL-8 release was also inhibited by all 
three MAP kinase inhibitors, but to a lesser degree (~30%). Unlike TT1 cells, ATII cell release 
of IL-6 fell significantly, to a similar extent (~20%; P < 0.05) for all three MWCNT formats, 
following treatment with each inhibitor. ATII cell MAP kinase inhibition was greater for IL-8 
release (~40%; P < 0.05, for all three inhibitors. However, the effect of ATII treatment with 
MAP kinase inhibitors on MCP-1 release varied between the three: inhibition of JNK and ERK 
1/2 caused a significantly greater reduction when compared with inhibition of p38. Indeed, MAP 
kinase inhibition was most marked in the ATII response to short, 0.6 μm MWCNTs, where 
inhibition of JNK and ERK 1/2 reduced MCP-1 release by 51% and 49%, respectively. There 
was a similar trend in ATII cell MAP kinase inhibition of MCP-1 with both the MWCNT-3μm 
and MWCNT-20μm formats, albeit less marked. Critically, these data indicate that different 
pathways may be involved in the TT1 and ATII epithelial cell responses to MWCNT exposure, 
and that ATII release of MCP-1 is via a different pathway to that of TT1, not involving p38. 
 
AMs displayed the greatest reduction in IL-8 release as a result of treatment with MAP kinase 
inhibitors (Figure 6). Inhibition of JNK, p38 and ERK 1/2 reduced the AM IL-8 response to 50 
μg/ml of MWCNT-0.6μm by 49%, 86% and 53% respectively. The profile of IL-8 inhibition was 
generally similar following exposure to MWCNT-3μm and MWCNT-20μm. Notably however, 
and unlike ATII cells, p38 was found to be the most important MAP kinase in the AM IL-8 
release response to MWCNT exposure, irrespective of MWCNT length. There was a small but 
significant effect of each inhibitor on AM IL-6 release (~20%), regardless of MWCNT length; 
  
 
27
there was no effect on AM MCP-1 release, again in contrast to the epithelial cell responses, 
likely reflecting the lack of impact of these MWCNTs on AM MCP-1 release. The role of MAP 
kinases in MWCNT bioreactivity with lung cells has been studied by others, with variable 
conclusions across other species. For example, Hirano et al showed that MWCNTs (10 - 100 
μg/ml) did not activate ERK 1/2, JNK or p38 in J774.1 mouse monocyte macrophages [25]. It is 
possible that the biointeraction of MWCNTs with mouse blood monocytes is different to that 
with human alveolar macrophages, thus we see contrasting observations in the present study. 
Furthermore, while the diameter of MWCNTs in the Hirano et al study was reported as 67 nm, 
their length was not determined. In agreement with the present study, Lee et al showed that 
MWCNTs (10 - 100 μg/ml; 10-30 μm in length, 20-30 nm in diameter) activate ERK 1/2 in 
RAW264.7 macrophages [39]. Additionally, an interesting co-culture study by Snyder-
Talkington et al showed that MWCNTs (1.2 μg/ml; ~4 μm in length, 50 nm in diameter) activate 
human small airway epithelial cells which in turn activate p38 in human microvascular 
endothelial cells [40]. The present study therefore highlights the importance of using 
representative human lung cell models to determine MWCNT bioreactivity, while it also reveals 
the possibility of intercellular responses by virtue of target alveolar epithelial cells/AMs being 
activated and subsequently activating other types of neighbouring lung cells. The latter is 
currently under investigation in our laboratory.  
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Figure 6. Effect of MAP kinase inhibitors on inflammatory mediator release from MWCNT-
treated TT1 and ATII epithelial cells and AMs.  To examine the effect of MAP kinase signaling 
in MWCNT reactivity with TT1 and ATII epithelial cells and AMs, we inhibited JNK, p38 and 
ERK 1/2 with SP600125, SB203580 and PD98059, respectively, prior to TT1, ATII and AM 
treatment with 50 μg/ml of each MWCNT format. IL-6, IL-8 and MCP-1 releases are expressed 
with respect to releases by TT1 and ATII cells and AMs in the absence of MAP kinase 
inhibitors. Significance is indicated where *P < 0.05, **P < 0.01 ***P < 0.001. 
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4. Conclusion 
Exposure to MWCNTs through inhalation could activate the pulmonary alveolar 
epithelium and alveolar macrophages, resulting in a pro-inflammatory response and possibly 
longer term, chronic pathology, depending on the exposure load. We studied the effect of well-
characterised MWCNTs using highly relevant and primary human lung cell models, to address 
the hypothesis that increased aspect ratio would be a critical determinant of any cytotoxicity and 
bioreactivity. We used three MWCNT formats with different lengths (MWCNT-0.6μm, 
MWCNT-3μm and MWCNT-20μm), but comparable diameters (~30nm), surface charges 
(negative) and carbon purities (~92%). We have shown that all three MWCNTs caused adverse 
effects, where bioreactivity depended on MWCNT length. Unexpectedly, and in contrast to our 
original hypothesis, the severity of the effect also depended on the cell type exposed. Shorter 
MWCNTs were more reactive with the TT1 and ATII epithelial cells, even at very low 
concentrations, for all inflammatory mediators. However, long MWCNTs had virtually no effect 
on IL-6 and IL-8 release from the epithelial cells, and a reduced effect on MCP-1 release. In 
direct contrast, the longer MWCNTs were more reactive with the AMs, causing significant cell 
death and stimulating significant increases in IL-6 and IL-8. Nevertheless, the shorter MWCNTs 
did induce AM IL-6 and IL-8 release, however this was relatively lower and decreased in 
relation to decreasing MWCNT length. The inability of MWCNTs to induce MCP-1 release by 
AMs is also interesting. The pro-inflammatory effect of these MWCNT formats was found to 
correspond to MAP kinase signalling, the relative role differing according to cell type and 
mediator released. Our discovery that the short MWCNTs induce the greatest responses from 
alveolar epithelial cells, without significant cell death, opens up a number of possibilities, that, 
following inhalation of short MWCNTs, these cells (particularly ATII cells, which release higher 
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levels of mediators under the same experimental conditions) might orchestrate the inflammatory 
response and subsequent interstitial/cardiovascular events. 
 
MWCNTs of different lengths have numerous commercial applications and can therefore all be 
considered a potential respiratory hazard. This unique study, comparing responses between a 
human alveolar type-I-like epithelial cell line, and primary human ATII epithelial cells and AMs 
from the same donor subjects, allows us to draw strong conclusions as to the lung-cell-specific 
pro-inflammatory response to MWCNTs of different lengths and furthermore, highlights the 
inadequacy of using a single cell model for nanomaterial safety screening.  
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